2026-01-10 - Analysis Report
Okay, here's a comprehensive report on Natera Inc. (NTRA), analyzing the provided data:

**0) Report Overview**

This report examines Natera Inc. (NTRA) based on its recent stock performance, financial metrics, market indicators, news, and analyst opinions. It compares NTRA's return rate against the S&P 500 (VOO), analyzes various technical indicators, and summarizes recent news and earnings data.

**1) Return Rate vs. S&P 500 (VOO) and Alpha/Beta Analysis**

*   **Company Overview:** Natera Inc. is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer diagnostics.
*   **Cumulative Return (NTRA):** 136.79%
*   **Cumulative Return (VOO):** 92.74%
*   **Divergence:** 35.3 (Relative Divergence: 47.5)

**Analysis:** Natera has significantly outperformed the S&P 500 over the examined period. The divergence of 35.3 indicates that Natera's cumulative return is higher than the S&P 500 by that percentage. The relative divergence of 47.5 suggests that the current divergence is positioned in the middle of the fluctuation range when compared to the minimum and maximum divergence observed in the past.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2016-2018  | 16.0%   | 56.0%  | 13.0%   | 1.5   | 1.9    |
| 2017-2019  | 49.0%   | 58.5%  | 32.0%   | 1.7   | 4.6    |
| 2018-2020  | 177.0%  | 58.5%  | 156.0%  | 1.3   | 13.6   |
| 2019-2021  | 89.0%   | 33.9%  | 46.0%   | 1.4   | 12.7   |
| 2020-2022  | -74.0%  | 76.8%  | -72.0%  | 1.4   | 5.5    |
| 2021-2023  | -183.0% | 76.8%  | -184.0% | 1.6   | 8.5    |
| 2022-2024  | 11.0%   | 60.6%  | -9.0%   | 1.5   | 21.6   |
| 2023-2025  | 158.0%  | 39.0%  | 95.0%   | 1.3   | 31.2   |

**Analysis:**

*   **CAGR:** Shows fluctuating annual growth, with strong positive returns in 2018-2020 and 2023-2025 but significant losses in 2020-2022 and 2021-2023.
*   **MDD:** Natera experiences substantial drawdowns, indicating high volatility.
*   **Alpha:** Shows Natera's performance relative to the market. Positive alpha values indicate outperformance, while negative values indicate underperformance.
*   **Beta:** Consistently above 1, indicating that Natera is more volatile than the overall market (S&P 500).
*   **Cap(B):** Market capitalization is increasing.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 239.56
*   **Last-market:** Price: 234.31, Previous Close: 239.56, Change: -2.19
*   **5-day SMA:** 241.79
*   **20-day SMA:** 233.69
*   **60-day SMA:** 217.37

**Analysis:**

*   The last market price showed a small change of -2.19.
*   The 5-day SMA is above the 20-day and 60-day SMAs, suggesting a short-term upward trend. However, the 20-day SMA is above the 60-day SMA, indicating a mid-term uptrend.

**3) RSI, PPO, MRI, and Expected Return**

*   **MRI:** 0.7 (Medium Investment Recommended)
*   **RSI:** 61.93
*   **PPO:** 0.26
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.70)
*   **Recent Relative Divergence Change:** -2.0 (Short-term Decrease)
*   **Expected Return:** -45.1%

**Analysis:**

*   **MRI:** A value of 0.7 suggests a medium level of market risk, making it a moderately attractive investment.
*   **RSI:** An RSI of 61.93 indicates that the stock is approaching overbought territory (above 70), but it is not there yet.
*   **PPO:** A positive PPO suggests that the short-term moving average is above the long-term moving average, which can be a bullish signal.
*   **Hybrid Signal:** Suggests buying with caution.
*   **Relative Divergence Change:** The recent decrease in relative divergence suggests short-term downward pressure.
*   **Expected Return:** The expected return of -45.1% is concerning, indicating potential underperformance compared to the S&P 500 over a long-term investment horizon.

**4) Recent News & Significant Events**

*   **[2025-12-20] Natera (NTRA): Assessing Valuation After a Multiâ€‘Year Share Price Surge:** Indicates market attention on Natera's valuation due to significant gains.
*   **[2026-01-07] Natera (NTRA) announces publication of findings from randomized, phase III CALGB (Alliance)/SWOG 80702 study:** Positive trial data can positively influence the stock price.
*   **[2026-01-08] A diagnostics veteran joins Octave to scale precision care for brain disease:** This is not related to NTRA.
*   **[2026-01-08] Assessing Natera (NTRA) Valuation After Positive ALTAIR Trial Data And Expanded Fetal Focus Test Launch:** Further valuation discussion, likely prompted by recent trial data and product expansion.
*   **[2026-01-07] Citigroup Initiates Buy Rating on Natera (NTRA) with $300 Price Target:** A strong buy rating from a major financial institution can drive investor confidence and potentially increase the stock price.
*   **[2025-12-11] Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks:** Inclusion on Druckenmiller's portfolio list is generally positive.

**Analysis:** The recent news is mixed but leans positive. Positive trial data, a buy rating from Citigroup, and inclusion in Druckenmiller's portfolio could boost investor sentiment. However, ongoing valuation assessments might introduce volatility.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (1.45 on a 1-5 scale)
*   **Opinions:** 20
*   **Target Price (Avg/High/Low):** $256.95 / $300.00 / $186.00

**Analysis:** Strong analyst consensus with a "Strong Buy" rating suggests that analysts are generally optimistic about Natera's future performance. The average target price of $256.95 indicates potential upside from the current price of $234.31.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue  |
|------------|-------|----------|
| 2025-11-07 | -0.64 | 0.59 B$  |
| 2025-08-08 | -0.74 | 0.55 B$  |
| 2025-05-09 | -0.50 | 0.50 B$  |
| 2024-11-12 | -0.26 | 0.44 B$  |
| 2025-11-07 | -0.26 | 0.44 B$  |

**Analysis:**

*   Natera is consistently reporting negative EPS, indicating that the company is not yet profitable.
*   Revenue is growing steadily, which is a positive sign. The growth in revenue suggests increasing adoption of Natera's products and services.
*   The provided table has duplicate of 2024-11-12 data at 2025-11-07.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.59B  | 64.91%        |
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-09-30 | $1.25B  | -6.99%  |
| 2025-06-30 | $1.25B  | -8.10%  |
| 2025-03-31 | $1.24B  | -5.40%  |
| 2024-12-31 | $1.20B  | -4.50%  |
| 2024-09-30 | $0.88B  | -3.60%  |

**Analysis:**

*   **Revenue:** Consistent revenue growth is observed, indicating increasing business activity.
*   **Profit Margin:** High and relatively stable profit margins suggest efficient operations.
*   **Equity:** Equity is increasing, which is a positive sign for the financial health of the company.
*   **ROE:** Negative ROE values indicate that the company is not generating profits from its equity. This aligns with the negative EPS reported earlier. The negative ROE improved from 2025-06-30 to 2025-09-30.

**7) Comprehensive Analysis (Summary)**

Natera Inc. (NTRA) presents a mixed picture.

*   **Strengths:**
    *   Strong historical outperformance against the S&P 500.
    *   Consistent revenue growth and high profit margins.
    *   Positive analyst consensus with a "Strong Buy" rating and a potential upside based on target prices.
    *   Positive news flow related to trial data and analyst upgrades.
*   **Weaknesses:**
    *   High volatility, as indicated by the MDD.
    *   Consistently negative EPS and ROE, indicating a lack of current profitability.
    *   Negative expected return, which is a concern for long-term investors.
    *   Declining trend on divergence, suggests short-term decline.

*   **Overall:** Natera's high growth potential is tempered by its current lack of profitability and high volatility. Investors should be aware of the risks and rewards before investing in NTRA.

**Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.